Sees FY23 U.S. XPOVIO net product revenue $110M-$125M, driven by the expectation that the increased use of PAP will continue in 2023, including a cumulative effect from refills. Sees FY23 non-GAAP R&D and SG&A expenses, which exclude stock-based compensation expense, $240M-$255M, as a result of cost savings from further optimization of infrastructure and cost structure and workforce reduction of approximately 20%. The Company continues to expect that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KPTI:
- Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- KPTI Upcoming Earnings Report: What to Expect?
- Karyopharm presents updated analyses from SIENDO study of selinexor
- Karyopharm Bags Orphan Drug Tag for Myelofibrosis Treatment
- Karyopharm receives FDA Track Designation for selinexor
